Arcutis Reports P-II Study Results of Roflumilast for the Treatment of Chronic Plaque Psoriasis
Shots:
- The open-label P-II study evaluates roflumilast (0.3%, qd). 2 cohorts of patients were enrolled (n=332) incl. Cohort-1 (n=230) who had completed the P-IIb trial @12wk. & participants in Cohort-2 (n=102) were recently enrolled (treatment-naïve)
- The results showed 57.1% achieved an IGA score of clear or almost clear (IGA 0/1) with a median duration of IGA of ≥10mos. (40.1wks). The results were consistent with the (DERMIS) trials, were safe & very well tolerated
- Participants prior treated with roflumilast & roflumilast-naïve, IGA success (35.3% & 37.5%), IGA score (IGA 0/1) @52wk. were 42% & 47.5% while I-IGA success in Cohort-21 (66.7%) with no tachyphylaxis & efficacy was consistent over time, rates of discontinuations due to AEs were low & no evidence of irritation (≥97%)
Ref: Globenewswire | Image: Arcutis
Related News :- Arcutis Reports P-III Trial (INTEGUMENT-2) Results of Roflumilast for the Treatment of Atopic Dermatitis in Adults and Children Aged ≥6 Years
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
